Literature DB >> 30656685

Hepatocyte-specific and extra-hepatocyte actions of perilipin-2 during fatty liver disease: benefits of being extra.

Lindsey Kennedy1, Heather Francis2,1, Gianfranco Alpini2,1.   

Abstract

Entities:  

Keywords:  NAFLD; NASH; Perilipin-2; Steatosis

Year:  2019        PMID： 30656685      PMCID： PMC6418740          DOI： 10.1113/JP277539

Source DB:  PubMed          Journal:  J Physiol        ISSN： 0022-3751            Impact factor:   5.182


× No keyword cloud information.
  4 in total

1.  Perilipin-2 promotes obesity and progressive fatty liver disease in mice through mechanistically distinct hepatocyte and extra-hepatocyte actions.

Authors:  David J Orlicky; Andrew E Libby; Elise S Bales; Rachel H McMahan; Jenifer Monks; Francisco G La Rosa; James L McManaman
Journal:  J Physiol       Date:  2019-01-02       Impact factor: 5.182

Review 2.  Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance.

Authors:  O F James; C P Day
Journal:  J Hepatol       Date:  1998-09       Impact factor: 25.083

3.  Perilipin-2-null mice are protected against diet-induced obesity, adipose inflammation, and fatty liver disease.

Authors:  James L McManaman; Elise S Bales; David J Orlicky; Matthew Jackman; Paul S MacLean; Shannon Cain; Amanda E Crunk; Ayla Mansur; Christine E Graham; Thomas A Bowman; Andrew S Greenberg
Journal:  J Lipid Res       Date:  2013-02-12       Impact factor: 5.922

4.  Hepatic expression patterns of inflammatory and immune response genes associated with obesity and NASH in morbidly obese patients.

Authors:  Adeline Bertola; Stéphanie Bonnafous; Rodolphe Anty; Stéphanie Patouraux; Marie-Christine Saint-Paul; Antonio Iannelli; Jean Gugenheim; Jonathan Barr; José M Mato; Yannick Le Marchand-Brustel; Albert Tran; Philippe Gual
Journal:  PLoS One       Date:  2010-10-22       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.